Compounding Pharmacies Market (2026 - 2033)

Compounding Pharmacies Market Summary

The global compounding pharmaciesmarket was valued at USD 17.6 billion in 2025 and is projected to grow from USD 18.9 billion in 2026 to USD 31.4 billion in 2033, at a CAGR of 7.5% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 43.0% in 2025. The increasing importance of compounding for enhancing medication adherence is one of the major factors driving the market's growth. The ability of compounding pharmacies to address the critical gap left by commercial pharmaceutical companies, personalized medication requirements, and drug shortages is expected to fuel market growth.

Medication adherence can be challenging for patients due to various factors, such as swallowing issues, taste preferences, or allergies to certain ingredients in commercially available medications. Compounding pharmacies specialize in creating personalized medications tailored to individual patient needs, addressing adherence barriers by providing customized dosage forms, flavors, and allergen-free formulations to enhance patient acceptance and compliance, ultimately driving demand for their services.

Market Dynamics

Analyst Perspective

A shift toward personalized medicine is primary driving factor for this industry, with heavy investments by major market participants in improving R&D effort and alteration capabilities with professionally trained teams. Key trend in this industry includes a transition of certain compounding businesses from traditional community-based models to large-scale, corporate businesses, with multiple stores. In addition, technology advancements and inclusion of modern processes backed by automation and robotics also shape the future course of this market.

Therapeutic Area Insights

The pain management segment dominated the market with the largest revenue share of over 33.0% in 2025. The high share of the segment can be attributed to the growing prevalence of chronic pain and side effects associated with commercially available pain management medications. The compounded pain management medications have several benefits, including bypassing the Gastrointestinal (GI) system for patients experiencing GI side effects and combining multiple medications in a single dose.

The nutritional supplements segment is anticipated to witness the fastest growth rate over the forecast period. This can be attributed to the growing demand for personalized beauty and anti-aging products. Hence, to cater to this demand, many companies are offering a range of compounded nutraceutical products. For instance, Medisca Inc. offers more than 100 compounded nutraceutical products, including prenatal multivitamins, minerals, antioxidants, and other supplements, all tested for heavy metals. Hormone replacement therapy often requires personalized formulations to meet each patient's unique needs. Compounding pharmacies specialize in creating customized hormone medications tailored to specific patient preferences and hormone levels.

Age Cohort Insights

Based on the age cohort, the market is divided into adult, pediatric, and geriatric. The adult segment dominated the market with the largest revenue share of more than 44.0% in 2025. Adult patients may require personalized medication due to the factor such as sensitivities to certain ingredients and specific dosage strengths. These demands can be met by compounding pharmacies, which can create tailored medications in the form of creams, capsules, or gels.

The pediatric segment is expected to witness the fastest growth rate over the forecast period. Children often require customized medications due to their smaller size, preferred tastes, limited dosage options, and difficulties swallowing solid dosage forms. These customized medications aim to improve medication adherence for young patients.

Sterility Insights

Based on sterility, the market is segmented into sterile and non-sterile. The sterility segment dominated the market with the largest share and accounted for more than 58.0% in 2025. It is expected to expand further at the fastest growth rate over the forecast period. The growth of the segment can be attributed to the rising demand for sterile-compounded medications in various healthcare settings. Furthermore, the rising complexity of patient needs and advancements in medical treatments may also contribute to the growth of the segment.

The non-sterility segment can address therapeutic gaps where commercially available medications may not meet specific patient needs. Compounded medications in non-sterile forms can be specially formulated to accommodate allergies, sensitivities, or unique patient requirements not met by mass-produced drugs. The flexibility and versatility of non-sterile compounding also play a major role in driving the market’s growth.

Compounding Type Insights

Based on the compounding types, the PIA segment dominated the market with the largest share and accounted for more than 37.0% in 2025. It is also expected to witness the fastest growth rate over the forecast period. A significant demand for compounded medications involves modifying or altering pharmaceutical ingredients to meet specific patient needs. PIA involves altering the composition or concentration of active ingredients in medications, often to customize them for individual patients.

PDA is an essential aspect of compounding pharmacies and involves adjustments in dosages based on specific patient requirements, patient age, medical condition, ingredient potency, and more. This is often done for pediatric and sensitive geriatric patients, to address problems such as swallowing.

Regional Insights

North America dominated the market with the largest share and accounted for more than 43.0% in 2025. The presence of several compounding pharmacies and strong strategic growth developments initiated by these companies highlight the growth potential of this market. For instance, in December  2025, Fagron announced acquisition of Amber Compounding Pharmacy in Southeast Asia and Vepakum in Brazil. In addition, it also announced obtaining a license for its Tampa-based Anazao Health facility from California State Board of Pharmacy.

Europe Compounding Pharmacies Market Trends

Europe held a significant market share of the global compounding pharmacies market in 2025. The aging population and advancements in medical treatments are contributing to the growth of the market in Europe. In addition, regulatory frameworks and guidelines, such as those set by the European Directorate for the Quality of Medicines (EDQM), aid in ensuring the safety, quality, and standardization of compounded medications, further supporting the growth of the industry.

Asia Pacific Compounding Pharmacies Market Trends

The market in the Asia Pacific region is expected to witness the fastest growth rate over the forecast period. The increasing demand for personalized medications, rising prevalence of chronic diseases, expansion of healthcare infrastructure, and increasing awareness about and demand for alternative therapies are the key factors driving the market growth.

Key Compounding Pharmacies Company Insights

The market is highly fragmented due to the presence of many independent pharmacies operating in different regions. The industry participants are focusing on development and innovation while implementing strategic business moves to sustain the competition. For instance, in May 2026, Fagron acquired University Compounding Pharmacy in North America, based in San Diego.

Key Compounding Pharmacies Companies

The following key companies have been profiled for this study on the compounding pharmacies market.

• Walgreen Co.

• Fagron

• Albertsons Companies

• The London Specialist Pharmacy Ltd

• Galenic Laboratories Limited

• Aurora Compounding Pharmacy

• Meds Apotek AB

• Apollo Hospitals Enterprise Limited

• Formul8

• Fusion Apothecary

• JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy)

Recent developments

• In December 2025, Wolters Kluwer N.V. launched newly developed compounding module for Simplifi 797, enabling pharmacies to address 2023 USP Chapter 797 requirements.

• In March 2025, MediVera Compounding Pharmacy announced opening of its newly developed facility in Michigan, U.S. This recently established 56,000-square-foot facility is expected to strengthen its position in market, while adding significant strength to its quality and innovation capabilities.

Compounding Pharmacies Market Report Scope

Global Compounding Pharmacies Market Report Segmentation

This report forecasts revenue growth at the regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global compounding pharmacy market report on the basis of therapeutic area, age cohort, compounding type, sterility, and region:

• Compounding Pharmacies Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

  • Hormone Replacement Therapy

  • Pain Management

  • Specialty Drugs

  • Dermatology

  • Nutritional Supplements

  • Others

• Compounding Pharmacies Age Cohort Outlook (Revenue, USD Million, 2021 - 2033)

  • Pediatric

  • Adult

  • Geriatric

• Compounding Pharmacies Compounding Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical Ingredient Alteration (PIA)

  • Currently Unavailable Pharmaceutical Manufacturing (CUPM)   

  • Pharmaceutical Dosage Alteration (PDA)

  • Others

• Compounding Pharmacies Sterility Outlook (Revenue, USD Million, 2021 - 2033)

  • Sterile

  • Non-sterile

• Compounding Pharmacies Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Mexico

    • Brazil

    • Argentina

  • Middle East & Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait